Serological responses to candidate AIDS vaccines.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  AIDS Research and Human Retroviruses

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 7865290
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

  1993cited by this paper
• V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.

  1993cited by this paper
• Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

  1993cited by this paper
• Synergistic Neutralization of HIV-1 by Human Monoclonal Antibodies Against the V3 Loop and the CD4-Binding Site of gp120

  1992cited by this paper
• Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.

  1992cited by this paper
• A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.

  1991cited by this paper

• Specificity and polyreactivity of the antibody response during natural HIV-1 infection

  2006cites this paper
• Virus-like particles: designing an effective AIDS vaccine.

  2006cites this paper
• Construction, Characterization and Immunogenicity of Human Immunodeficiency Virus-Like Particles

  2005cites this paper
• HIV vaccine development: lessons from the past and promise for the future.

  2003cites this paper
• Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa

  2002cites this paper
• Induction of Neutralizing Antibodies and Gag-Specific Cellular Immune Responses to an R5 Primary Isolate of Human Immunodeficiency Virus Type 1 in Rhesus Macaques

  2001cites this paper
• Retroviral Immunology

  2001cites this paper
• A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.

  2001cites this paper
• A Human Immunodeficiency Virus Prime-Boost Immunization Regimen in Humans Induces Antibodies That Show Interclade Cross-Reactivity and Neutralize Several X4-, R5-, and Dualtropic Clade B and C Primary Isolates

  2000cites this paper
• Immunization with Recombinant Canarypox Vectors Expressing Membrane-Anchored Glycoprotein 120 Followed by Glycoprotein 160 Boosting Fails to Generate Antibodies That Neutralize R5 Primary Isolates of Human Immunodeficiency Virus Type 1

  2000cites this paper
• Assessment of HIV vaccine development: past, present, and future.

  2000cites this paper
• A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9.

  1999cites this paper
• Toward an HIV Type 1 Vaccine that Generates Potent, Broadly Cross-Reactive Neutralizing Antibodies

  1999cites this paper
• HIV vaccines.

  1999cites this paper
• Designing a Vaccine Against HIV

  1999cites this paper
• Neutralizing Antibodies in Sera from Macaques Infected with Chimeric Simian-Human Immunodeficiency Virus Containing the Envelope Glycoproteins of either a Laboratory-Adapted Variant or a Primary Isolate of Human Immunodeficiency Virus Type 1

  1998cites this paper
• Broadly reactive antibodies against a gp120 V3 loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1).

  1997cites this paper
• A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3

  1997cites this paper
• In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope

  1996cites this paper
• Potential for Adverse Reactions from HIV Vaccines

  1995cites this paper
• Phase I/II Preventive Vaccine Trials: Conference Summary

  1995cites this paper
• HIV preventive vaccines. Progress to date.

  1995cites this paper
• Progress in AIDS vaccine development.

  1995cites this paper
• HIV Preventive Vaccines

  1995cites this paper